Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $9.07 USD
Change Today -0.21 / -2.26%
Volume 300.0
As of 8:10 PM 07/2/15 All times are local (Market data is delayed by at least 15 minutes).

nobel biocare hold-unsp adr (NBHGY) Snapshot

Open
$9.07
Previous Close
$9.28
Day High
$9.07
Day Low
$9.07
52 Week High
07/29/14 - $9.99
52 Week Low
07/29/14 - $7.56
Market Cap
2.2B
Average Volume 10 Days
30.0
EPS TTM
--
Shares Outstanding
247.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for NOBEL BIOCARE HOLD-UNSP ADR (NBHGY)

Related News

No related news articles were found.

nobel biocare hold-unsp adr (NBHGY) Related Businessweek News

No Related Businessweek News Found

nobel biocare hold-unsp adr (NBHGY) Details

Nobel Biocare Holding AG operates in the field of implant-based dental restorations worldwide. It offers dental implants for various indications, bone types, and surgical protocols under the NobelActive, Brånemark System, and NobelReplace brands; high-precision individualized prosthetics and CAD/CAM systems for every indication, from a single tooth to edentulous jaws, on natural teeth and implants under the NobelProcera brand; and machined and TiUnite implants. The company also provides a range of individualized CAD/CAM abutments and a portfolio of prefabricated temporary and final abutments; biomaterials for soft tissue and bone regeneration under the creos brand; and removable and fixed implant-supported restorations. In addition, it offers NobelClinician software for enhanced diagnostics and treatment planning; and NobelGuide, a treatment concept for diagnostics, prosthetic-driven treatment planning biomaterials and guided implant surgery. Nobel Biocare Holding AG provides training and education, as well as a range of practice support and patient information materials to its customers. The company markets its products to dental healthcare professionals comprising oral surgeons, general practitioners, specialists, and laboratories. Nobel Biocare Holding AG was founded in 1981 and is headquartered in Kloten, Switzerland. As of November 14, 2014, Nobel Biocare Holding AG operates as a subsidiary of Danaher Corp.

2,552 Employees
Last Reported Date: 11/6/14
Founded in 1981

nobel biocare hold-unsp adr (NBHGY) Top Compensated Officers

Chief Executive Officer
Total Annual Compensation: SFr.2.0M
Compensation as of Fiscal Year 2013.

nobel biocare hold-unsp adr (NBHGY) Key Developments

Nobel Biocare Unveils New Cement-Free Solution for Molar Teeth Restoration

Nobel Biocare Holding AG has unveiled a new complete, cement-free posterior treatment solution developed for restoration of molar teeth. The solution features a choice of new wide-platform implants and restorative options designed specifically for the posterior region. Also being launched at IDS is an entire new parallel-walled implant system, NobelParallel Conical Connection (CC). Nobel Biocare's new complete posterior solution incorporates new 5.5 mm wide-platform (WP) implant options. Clinicians can choose from the NobelParallel CC WP and new NobelActive WP, both designed for optimized emergence profiles for large molar crowns.

Nobel Biocare Holding AG to Report Fiscal Year 2014 Final Results on Apr 28, 2015

Nobel Biocare Holding AG announced that they will report fiscal year 2014 final results on Apr 28, 2015

Nobel Biocare Announces Management Changes

Nobel Biocare announced that effective February 1, 2015, Mr. Tullio Di Dio will be appointed Chief Financial Officer of Nobel Biocare succeeding Mr. Oliver Walker as he has decided to leave the company to pursue his career interests outside Nobel Biocare. Mr. Di Dio joins Nobel Biocare with 23 years of finance experience including assignments at United Technologies, Roche and during the past 12 years with Danaher. Most recently, Mr. Di Dio served as Vice President, Finance for Beckman Coulter EMEA. He played an important role in integrating Beckman Coulter into Danaher.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NBHGY:US $9.07 USD -0.21

NBHGY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
DENTSPLY International Inc $51.39 USD -0.35
Osstem Implant Co Ltd 67,600 KRW +600.00
Straumann Holding AG SFr.260.00 CHF +0.25
Zimmer Biomet Holdings Inc $108.19 USD -1.02
View Industry Companies
 

Industry Analysis

NBHGY

Industry Average

Valuation NBHGY Industry Range
Price/Earnings 33.3x
Price/Sales 3.1x
Price/Book 5.0x
Price/Cash Flow 33.2x
TEV/Sales 2.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NOBEL BIOCARE HOLD-UNSP ADR, please visit www.nobelbiocare.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.